Chapter 1: Breakthrough in Cancer Treatment

Recent findings from a clinical trial indicate that a groundbreaking treatment significantly improves survival rates for individuals diagnosed with malignant mesothelioma, a rare and often aggressive cancer related to asbestos exposure.

The phase 3 clinical trial, conducted under the sponsorship of Polaris Pharmaceuticals, highlighted a remarkable advancement in the treatment of malignant pleural mesothelioma (MPM). This trial demonstrated that the combination of standard chemotherapy and a new drug, ADI-PEG20, resulted in a median survival increase of 1.6 months and quadrupled the 36-month survival rate compared to those receiving placebo chemotherapy.

These results are particularly vital considering the grim statistics surrounding MPM, where the 5-year survival rate typically ranges from 5% to 10%. This innovative therapy represents the first successful integration of chemotherapy with a metabolism-targeting drug specifically designed for MPM in the last twenty years.

The ATOMIC-meso trial, which is the culmination of two decades of research from Queen Mary's Barts Cancer Institute, was initiated following Professor Szlosarek's discovery that malignant mesothelioma cells lack a crucial protein known as ASS1, which is essential for synthesizing arginine. Leveraging this discovery, Szlosarek and his team focused on developing an effective treatment option for MPM patients.

Ongoing research is also evaluating the potential of ADI-PEG20 in treating other cancers such as sarcoma and glioblastoma multiforme, which are also reliant on arginine. The success seen in MPM treatment opens up possibilities for this chemotherapy to be utilized in various cancer types.

"It's truly remarkable to witness the research into the arginine deprivation of cancer cells yielding positive outcomes. This is a discovery I have championed since its inception in the lab, with ADI-PEG20 now enhancing the lives of patients suffering from mesothelioma."

~ Professor Szlosarek, Lead Researcher of the Study

Mick, who was exposed to asbestos while working in a factory boiler room during the 1970s, sought medical help in 2018 after experiencing unexplained weight loss and general malaise. He was subsequently diagnosed with mesothelioma, which led to anemia as a complication.

After participating in the ATOMIC-meso trial for two and a half years, Mick faced a recurrence of his mesothelioma and underwent another treatment phase involving immunotherapy. Despite experiencing heightened side effects, including encephalitis, his cancer has been effectively managed, allowing him to recently celebrate his 80th birthday.

Professor Szlosarek and his team are focused on understanding why certain patients, like Mick, derive significant benefits from ADI-PEG20, with the goal of extending these benefits to a wider patient population. The comprehensive research findings have been published in the Journal of JAMA Oncology.

Closing the Gap: Equity in Clinical Trials, Research and Patient Care - This video discusses the importance of equitable access to clinical trials and how it impacts patient care.

Chapter 2: Future Directions in Cancer Research

As the research continues, further investigations into ADI-PEG20's efficacy in other cancer types are underway. The potential for this innovative therapy to contribute to broader cancer treatment strategies is promising.

Breakthrough Cancer Trial Showing Success - This video highlights the advances in cancer trials and the implications for future treatments.

➱➱➱➱➱➱➱➱➱➱➱➱➱➱➱➱➱➱➱➱➱➱➱➱➱➱➱➱➱

Read my daily newsletter by subscribing to Faisal Khan on Substack.

Stay informed with the content that matters — Join my Mailing List.

➱➱➱➱➱➱➱➱➱➱➱➱➱➱➱➱➱➱➱➱➱➱➱➱➱➱➱➱➱